GRAIL, LLC (GRAL)vsEli Lilly and Company (LLY)
GRAL
GRAIL, LLC
$107.97
+33.68%
HEALTHCARE · Cap: $3.53B
LLY
Eli Lilly and Company
$1,170.45
+0.48%
HEALTHCARE · Cap: $994.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 48106% more annual revenue ($79.67B vs $165.26M). LLY leads profitability with a 33.5% profit margin vs -236.9%. LLY earns a higher WallStSmart Score of 76/100 (B+).
GRAL
Hold35
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Revenue surging 25.7% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
0.0% earnings growth
ROE of -15.8% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 30.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : GRAL
The strongest argument for GRAL centers on Debt/Equity, Price/Book, Revenue Growth. Revenue growth of 25.7% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : GRAL
The primary concerns for GRAL are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
GRAL carries more volatility with a beta of 3.25 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 35/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GRAIL, LLC
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics, particularly through its innovative blood tests designed for multi-cancer early detection (MCED). Utilizing proprietary genomic technologies, the company is committed to enhancing precision medicine by offering vital insights for proactive health management and improving patient outcomes. GRAIL is poised to address critical gaps in cancer screening and diagnostics, establishing itself as a pivotal entity in the dynamic oncology landscape, with the potential to significantly impact the future of cancer care.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?